EmbryoGen/ Blastgen for Couples With Implantation Problems or Previous Miscarriage
NCT ID: NCT02305420
Last Updated: 2018-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
100 participants
INTERVENTIONAL
2014-11-30
2017-06-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Results showed a highly significant effect of 44% relative improvement in ongoing implantation rate (p=0.001) in women who have previously miscarried (Ziebe et al 2013).
We wish to undertake a randomised Controlled trial to determine if EmbryoGen/BlastGen media improves pregnancy outcomes in women with recurrent implantation failure, recurrent miscarriage and poor embryo development when compared to standard media.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hyaluronan-enriched Medium and Euploid Blastocyst Transfers
NCT06165367
Comparative Study of Three Different Embryo Transfer Media in ICSI Cycles
NCT02792673
Clinical Trial of Novel Implantation Promoting Medium (EmbryoGlue) to Improve IVF Success Rates
NCT00588250
Gcsf Injection in Women With Repeated Implantaiton Failure
NCT02149277
Non-invasive Preimplantation Genetic Testing for Aneuploidies Using Cell-free DNA in Spent Culture Media
NCT04711239
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At oocyte retrieval each couple will be randomised using numbered envelopes containing pre randomised group allocations by a person uninvolved in the trial to:
1. BlastGen Group (n=50): culturing their embryos in ORIGIO standard, sequential culture mediums for 3 days (EmbryoGen included) then BlastGen media (GM-CSF containing media) for remaining 2 days or
2. Standard Media Group (n=50): culturing their embryos in Cook standard sequential medium for 5 days.
The best single embryo will be transferred on day 5.
The clinical staff and participating couple will be blinded as to whether BlastGen or standard media was used in culture to day 5. Fertility SA embryologists will not be blind as to which study group a couple is in and which media is being used. The embryos will be cultured using the usual methods and lab facilities by Fertility SA's current embryology staff members who will not be blind to the media being used.
Records on the outcome of the oocyte fertilisation, blastocyst development, implantation rate and pregnancy rates will be recorded, as is standard practice. Pregnancy scans will be carried out at 7 and 12 weeks. Live birth outcomes and any congenital anomalies will be recorded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EmbryoGen/BlastGen
EmbryoGen and BlasGen media containing GM-CSF 2ng/ml will be used in the experimental arm
The intervention is to use EmbryoGen/BlastGen
EmbryoGen/ BlastGen media
Embryos will be cultured in media containing Gm-CSF (EmbryoGen/ BlastGen media)
Control
Standard Cook sequential media
Standard Cook sequential media
Standard Cook IVF media will be used in the control arm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EmbryoGen/ BlastGen media
Embryos will be cultured in media containing Gm-CSF (EmbryoGen/ BlastGen media)
Standard Cook sequential media
Standard Cook IVF media will be used in the control arm
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged between 25 and 41 years
* 2 or more embryos transferred without a positive pregnancy outcome OR a history of at least 1 previous pregnancy loss, OR
* Poor embryo development (\<20% of embryo developing on time at Day 3 or no blastocyst above Grade 2 on Day 5)
Exclusion Criteria
* the use of another investigational drug within 30 days
* any severe chronic disease that would significantly influence an IVF cycle
* less than 3 follicles\>14mm on ultrasound on the day of HCG trigger
25 Years
41 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Adelaide
OTHER
FertilitySA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
FertilitySA
Adelaide, South Australia, Australia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rose RD, Barry MF, Dunstan EV, Yuen SM, Cameron LP, Knight EJ, Norman RJ, Hull ML. The BlastGen study: a randomized controlled trial of blastocyst media supplemented with granulocyte-macrophage colony-stimulating factor. Reprod Biomed Online. 2020 May;40(5):645-652. doi: 10.1016/j.rbmo.2020.01.011. Epub 2020 Jan 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
8114
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.